Biopharma | May 08, 2026
Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
Initiative aims to strengthen South-South collaboration and capacity building in biomedical research
Hair care & quick commerce shine
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
The agreement targets a long-standing technical hurdle in the field: maintaining chemical purity as RNA constructs extend beyond 100 nucleotides
The company highlights role of integrated genomics and multi-omics research at the Illumina Multiomics Summit India 2026 held in New Delhi and Bengaluru
The facility combines advanced diagnostics, bone marrow transplant evaluation, prenatal awareness, and multidisciplinary support services
The company plans to collaborate with European medical centres to expand adoption of its robotic microsurgery platform
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
The deal brings SAI — a key distributor serving pharmaceutical and nutraceutical manufacturers — into the Safic-Alcan Group’s expanding Asia footprint
Subscribe To Our Newsletter & Stay Updated
